Navigation Links
Morria Biopharmaceuticals Plc Initiates Phase I Clinical Study of MRX-4 in Allergic Rhinitis
Date:10/23/2007

LONDON, Oct. 23 /PRNewswire/ -- Morria Biopharmaceuticals Plc, a biopharmaceutical company focused on the development of novel anti-inflammatory drugs, today announced the initiation of a Phase I tolerance study of MRX-4 in 16 patients suffering from allergic rhinitis (AR).

The randomized, placebo-controlled, double blind clinical trial is the first of two modules focusing on safety for Morria's first human study in AR. MRX-4 is nasally administered as a single dose either with or without an allergen challenge to determine tolerance. Results are expected by the end of the fourth quarter of 2007.

"We are excited to be taking this significant step toward introducing a potentially safer, more effective and more affordable treatment option to the multibillion-dollar AR market," said Yuval Cohen Ph.D., President of Morria.

"There is a real and urgent need for novel, non-steroidal treatments for inflammatory diseases such as allergic rhinitis. Morria's drug platform could potentially offer such an alternative," said Peter Barnes, a professor at the National Heart & Lung Institute at Imperial College in London and Morria scientific advisory board member.

ABOUT ALLERGIC RHINITIS

Allergic rhinitis is a common condition that affects nearly 59 million people in the United States (nearly 20 percent of the population) with a market of nearly $4 billion. Allergic rhinitis is characterized by inflammation of the nasal membranes accompanied by symptoms that may include sneezing, nasal congestion, nasal itching and rhinorrhea.

ABOUT MORRIA BIOPHARMACEUTICALS Plc

Morria Biopharmaceuticals Plc is a biopharmaceutical company focused on the development of novel anti-inflammatory pharmaceuticals known as multi-functional anti-inflammatory drugs (MFAIDs). This class of drugs uniquely combines two promising approaches to preventing and reversing inflammation: first, they control the phospholipase A2 (PLA2) enzyme family, a known but previous
'/>"/>

SOURCE Morria Biopharmaceuticals Plc
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2

Related medicine technology :

1. Inspiration Biopharmaceuticals Presents Data From Hemophilia Program at International Society On Thrombosis and Haemostasis (ISTH) Annual Meeting
2. Keryx Biopharmaceuticals, Inc. Announces Positive Phase I and Phase II Data on KRX-0401 in Patients with Relapsed/Refractory Multiple Myeloma and Waldenstroms Macroglobulinemia
3. Accentia Biopharmaceuticals Announces Favorable Interim Blinded Data on SinuNase in Its Fast-Tracked Pivotal Phase 3 Clinical Trial for Chronic Sinusitis
4. Keryx Biopharmaceuticals, Inc. Announces Poster Presentations Highlighting Mechanism of Action and Clinical Activity of Sulonex(TM) (sulodexide oral gelcap) at the Upcoming American Diabetes Association 67th Scientific Sessions in Chicago, Illinois
5. Accentia Biopharmaceuticals Scientific Presentations Demonstrate Increasing Acceptance of Fungal Etiology of Chronic Sinusitis at the Annual Meeting of the American Academy of Allergy, Asthma, and Immunology
6. Malvern initiates European user group meetings for chemical imaging
7. Data Available From Erbitux Phase III Study in First-Line Treatment of Advanced Lung Cancer
8. Phase 3 Results for Dabigatran Etexilate, an Investigational Oral Anticoagulant, Presented Today at the XXIst Congress of the International Society on Thrombosis and Haemostasis
9. YM BioSciences Announces Secondary Efficacy and Safety Findings in Randomized Phase IIB Aerolef Trial
10. Portola Pharmaceuticals Announces Positive Data from a Phase II Study of its Factor Xa Inhibitor at the XXI Congress of the International Society on Thrombosis and Haemostasis
11. Manhattan Pharmaceuticals Announces Results of Phase 2a Studies for Oral Oleoyl-estrone
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/27/2015)... HILL, N.C. , March 27, 2015  The ... intimidating job description: ensure products meet quality standards at ... budgets and escalating regulations, quality leaders also have the ... and risk. Those who don,t effectively balance ... function as well as marketplace failure and regulatory scrutiny. ...
(Date:3/27/2015)... -- Dynatronics Corporation (NASDAQ: DYNT ) today announced that ... Company,s Board of Directors effective March 23, 2015, to fill ... board member Joseph Barton .  "The ... Directors represents an important step forward for the company," said ... "Rich is a proven leader and is well-known for his ...
(Date:3/27/2015)... -- The Temple Health & Bioscience District (THBD) today announced ... 1802 South First St. in the Temple Medical and Education ... City of Temple to receive funding for redevelopment. ... Veterans Health Care System, the new facility will enable THBD ... and life science companies. Temple ...
Breaking Medicine Technology:New Medical Device Quality Study Finds Regulatory Environment is Boosting Quality Spending, Especially for Large Companies 2Dynatronics Announces Appointment of Richard J. Linder to Board of Directors 2Temple Health & Bioscience District Relocates, Offers Office And Lab Space To Biotech Companies 2
... 26 Healthy Advice ® Networks, the ... consumers and physicians, is pleased to announce they ... award-winning consumer health information once again by the ... such renowned institutions as the Mayo Clinic and ...
... Medco Health Solutions, Inc. (NYSE: MHS ) ... to help protect themselves against certain unnecessary health risks.  The ... of gaps in care that could harm their health and ... was announced today at Medco,s Best Practices Workshop, an annual ...
Cached Medicine Technology:Healthy Advice® Networks Wins 39 National Health Information Awards 2Healthy Advice® Networks Wins 39 National Health Information Awards 3Medco Launches Online Safety Net to Increase Adherence and Prevent Avoidable Medication Risks 2Medco Launches Online Safety Net to Increase Adherence and Prevent Avoidable Medication Risks 3Medco Launches Online Safety Net to Increase Adherence and Prevent Avoidable Medication Risks 4
(Date:3/29/2015)... Youth Villages will participate in a partnership with ... feasibility of implementing a Pay for Success model to ... families. , Third Sector Capital Partners Inc. ran a ... technical assistance throughout 2015 toward a Pay for Success ... chosen by Third Sector. The organization’s work with the ...
(Date:3/29/2015)... North American Seminars receives Texas Board ... Education Courses . , Utilizing Pilates to ... TPTA, approval # 56399TX      , The Interactive ... complex - 10.5 hours - Texas Board of Physical ... Treatment of the SI Joint - 10 hours - ...
(Date:3/28/2015)... Rocket Pure , a manufacturer of ... of their new natural sunscreen. They are offering the ... Both options come with a bonus lip balm sunscreen. , ... Amazon. Click to see the natural sunscreen on ... sunscreen is made with non-nano zinc oxide and provides broad-based ...
(Date:3/28/2015)... March 28, 2015 Could genetic code ... new study by researchers at the Harvard ... with the support of the Coffee and Caffeine Genetics ... Psychiatry this past fall, the study—one of several recent ... genomic data from more than 120,000 regular coffee drinkers ...
(Date:3/28/2015)... 2015 Take a bite of warm, ... action. Acids tumble into the stomach, ready to break ... structure lets these acids run amok, triggering a burning ... symptom. More than 60 million Americans have heartburn at ... heartburn starts, and how it can be stopped. , ...
Breaking Medicine News(10 mins):Health News:Youth Villages Partners with Two Oregon Counties to Advance Pay-for-Success Model to Help At-Risk Youth 2Health News:Youth Villages Partners with Two Oregon Counties to Advance Pay-for-Success Model to Help At-Risk Youth 3Health News:Youth Villages Partners with Two Oregon Counties to Advance Pay-for-Success Model to Help At-Risk Youth 4Health News:Rocket Pure Releases New Natural Sunscreens For Athletes 2Health News:Rocket Pure Releases New Natural Sunscreens For Athletes 3Health News:How Coffee Habits Relate to Our Genetic Code and Enhancing the Caffeine Experience 2Health News:How Coffee Habits Relate to Our Genetic Code and Enhancing the Caffeine Experience 3Health News:Bypass Your Heartburn Worries This Easter With Tylers Coffee 2
... Jerusalem, Nov. 9, 2009 Research carried out among thousands ... a loss of bone mass, leading to osteoporosis and fractures. ... researchers, Prof. Raz Yirmiya, head of the Brain and Behavior ... They further revealed that the relationship between depression and bone ...
... SAN DIEGO, Nov. 9 Renewal Laboratories announced today ... produce functional beverages with important anti-oxidants and omega3 fatty ... Q10, resveratrol, and omega3 fish oil may now be ... company will soon premier a unique line of all ...
... Doctor house calls now ... ... pain management physician, will now offer routine house calls to residents of Manhattan in New York ... at 212-918-1629 or sending an email from davisbregman.com . The convenience of being able to ...
... ... both CAMTS and EURAMI accreditation and Department of Defense approval, , ... Birmingham, AL (PRWEB) November 9, 2009 ... full accreditation from the European Aero-Medical Institute (EURAMI). EURAMI is a Stuttgart, Germany, ...
... Bregman , a pain management physician will now offer routine house ... be able to request a house call by ... davisbregman.com . The convenience of being able to see the ... this new way of seeing most patients. The service will be ...
... O,Brien, president of Catholics for Choice, issued the following statement ... recent weeks tells us and the American voters a lot ... to our core values, seeking to overcome the struggles ordinary ... cannot afford basic healthcare or have to choose between maintaining ...
Cached Medicine News:Health News:Connection between depression and osteoporosis detailed by Hebrew University researchers 2Health News:Renewal Laboratories(TM) Announces the First Omega3 Supplement Water for Cardiac Health 2Health News:Davis Bregman MD Now Offering House Calls in Manhattan 2Health News:AirMed International, Top U.S. Air Ambulance, Receives EURAMI Accreditation 2Health News:Davis Bregman MD Now Offering House Calls in Manhattan 2Health News:Catholics for Choice Statement on Healthcare Reform Bill 2
Determination of Prothrombin Time (PT) by STA Analyzers (ISI~1.3).Freeze-dried rabbit brain thromboplastin with heparin inhibitor....
For the quantitative in vitro determination of creatinine in serum, plasma or urine....
For the quantitative in vitro determination of Magnesium in serum, plasma and urine...
For the quantitative in vitro determination of Anti-Streptolysin-O (ASO) in serum...
Medicine Products: